, Volume 18, Issue 5, pp 209–221 | Cite as

Gastric cytoprotection 30 years after its discovery by André Robert: a personal perspective



It is generally accepted that the development of gastric mucosal injury and protection is a consequence of an imbalance between the existing aggressive and defensive factors in the gastric mucosa. The excess secretion of gastric acid and increased production of pepsin have been considered as the main etiological factors in the development of peptic ulcer diseases in humans. André Robert and his coworkers (Kalamazoo, Michigan, USA) identified a new pathway for the gastric mucosal protection against the gastric mucosal damage injury (e.g. from HCl, NaOH, NaCl, ethanol, or thermal injury) by small doses of prostaglandins (1–5 μg/kg given ig or sc), without presence of any gastric acid secretory properties in rats. This phenomenon was termed “gastric cytoprotection” (1979). The results of this basic research offered a lot of new possibilities to test this hypothesis in different experimental models under different experimental conditions, in both human healthy subjects as well as in patients with various gastrointestinal disorders (acute and chronic gastrointestinal inflammatory conditions in the stomach and intestines, as well as GI precancerous states, i.e., oesophageal, stomach, pancreatic, liver and colon cancers). An international symposium on “gastric cytoprotection: 30 years after André Robert’s concept” was organized at Split (Croatia) on September 13, 2009, at which invited experts from China, Croatia, Italy, Japan, Poland, and USA gave presentations and discussed the studies performed in the field of cytoprotection between 1979 and 2009. This paper provides a short critical summary of this meeting in the context of an “official historic background” of the events underlying the discovery of “gastric cytoprotection” which originated from the pioneering work of André Robert.


Gastroprotection Cytoprotection Animal experiments Human observations 



The author wishes to express his sincere thanks to Professor K.D.Rainsford (Shefield University, U.K.) for his valuable help and criticism in the preparation of this paper. The author expresses his thanks to Viktoria Vas (First Department of Medicine, University of Pécs, Hungary) for the preparation of the manuscript and the references.


  1. Abdel-Salam OME, Mózsik Gy, Szolcsányi J (1995) Studies on the effect of intragastric capsaicin on gastric ulcer and on the prostacyclin-induced cytoprotection in rats. Pharmacol Res 32:209–215CrossRefPubMedGoogle Scholar
  2. Bjarnason I, Smethurst P, Macpherson A, Walker F, McElnay JC, Passmore AP, Menzies IS (1992) Glucose and citrate reduce the permeability changes caused by indomethacin in humans. Gastroenterology 102:1546–1550PubMedGoogle Scholar
  3. Bódis B, Karádi O, Abdel-Salam OME, Vörös S, Nagy L, Mózsik Gy (1996) Direct cellular effect of Helicobacter pylori alone and with cotreatments of ethanol and indomethacin in mixed isolated rat gastric mucosa cell. Dig Dis Sci 41:430Google Scholar
  4. Bódis B, Németh P, Mózsik Gy (1998) Organoprotection and cytoprotection in the stomach. Akadémiai Kiadó, BudapestGoogle Scholar
  5. Brzozowski T, Konturek PC, Kwiecien S, Pajda R, Pawlic M, Drozdovicz D, Konturek SJ, Pawlik WW (2009) Ischemic preconditioning—a form of adaptive cytoprotection. J Physiol Pharmacol 60(Suppl 2):17Google Scholar
  6. Cho CH (2009) Cathelidin on mucosal repair. J Physiol Pharmacol 60(Suppl 2):18Google Scholar
  7. Filaretova LP (2006) The hypothalamic-pituitary-adrenocortical system: hormonal brain-gut interaction and gastroprotection. Auton Neurosci 125:86–93Google Scholar
  8. Filaretova LP, Filaretov AA, Makara GB (1998) Corticosteron increase inhibits stress-induced gastric erosions in rats. Am J Physiol 274:G1024–G1030Google Scholar
  9. Filaretova LP, Bagaeva TR, Makara GB (2002) Aggravation of nonsteroidal anti-inflammatory drug gastropathy by glucocorticoid deficiency or blockage of glucocorticoid receptors in rats. Life Sci 71:2457–2468Google Scholar
  10. Filaretova LP, Bagaeva TR, Amagase K, Takeuchi K (2008) Contribution of glucocorticoids to protective influence of preconditioning mild stress against stress-induced gastric erosions. Ann N Y Acad Sci 1148:209–212Google Scholar
  11. Gustafson J, Welling D (2010) “No acid, no ulcer”—100 years later: a review of the history of peptic ulcer disease. J Am Coll Surg 210:110–116CrossRefPubMedGoogle Scholar
  12. Guth PH, Aures D, Paulsen G (1979) Topical aspirin plus HCL gastric lesions in the rat. Cytorpotective effect of prostaglandin, cymetidine and probanthine. Gastroenterology 76:88–93PubMedGoogle Scholar
  13. Gyires K, Zádori ZS, Shujaa N, Al-Khrasani M, Pap B, Mózes MM, Mátyus P (2009) Pharmacological analysis of alpha(2)-adrenoceptor subtypes mediating analgesic, anti-inflammatory and gastroprotective actions. Inflammopharmacology 17(3):171–179Google Scholar
  14. Holzer P (1991) Capsaicin:cellular targets, mechanisms of action, and selectivity for thin sensory neurons. Pharmacol Rev 43:144–202Google Scholar
  15. Holzer P (1998) Neural emergency system in the stomach. Gastroenterology 114:823–839Google Scholar
  16. Jávor T, Bata M, Kutor G, Lovász L, Mózes Gy, Tárnok F, Mózsik Gy (1981) Gastric mucosal resistance to physical and chemical stress. In: Mózsik Gy, Hänninen O, Jávor T (eds) Advances in Physiological Sciences. Vol. 29. Gastrointestinal Defefense Mechanisms. Pergamon Press Oxford, Akadémiai Kiadó, Budapest, pp 141–159Google Scholar
  17. Jávor T, Bata M, Lovász L, Morón F, Nagy L, Patty I, Szabolcs J, Tárnok F, Tóth Gy, Mózsik Gy (1983) Gastric cytoprotective effect of vitamin A and other carotenoids. Int J Tiss React 5:89–296Google Scholar
  18. Lacy ER, Ito S (1984) Rapid epithelial restitution of the rat gastric mucosa after ethanol injury. Lab Invest 51:573–583PubMedGoogle Scholar
  19. Miller TA (1983) Protective effects of prostaglandins against gastric mucosal damage: current knowledge and proposed mechanisms. Am J Physiol Gastrointest Liver Physiol 245:G601–G623Google Scholar
  20. Morón F, Pena C, Cuesta E, Mózsik Gy, Jávor T (1984) Comparative study of the cytoprotective effects of anticholinergic agents on the gastric mucosal lesions produced by intragastric administration of 0.6 M HCl in rats. Acta Physiol Hung 64:247–252PubMedGoogle Scholar
  21. Mózsik Gy (2005) Neural, hormonal and pharmacological regulations of retinoids-induced gastrointestinal mucosal protection. Recent Res Develop Life Sci 3:131–202Google Scholar
  22. Mózsik Gy (2006) Molecular pharmacology and biochemistry of gastroduodenal mucosal damage and protection. In: Mózsik Gy (ed) Discoveries in Gastroenterology. From Basic Research the Clinical Perspectives (1960–2005). Akadémiai Kiadó, Budapest, pp 139–224Google Scholar
  23. Mózsik Gy, Jávor T (1969) Development of drug cross-tolerance in patients treated chronically with atropine. Eur J Pharmacol 6:169–174CrossRefPubMedGoogle Scholar
  24. Mózsik Gy, Jávor T, Dobi S (1965) Clinical pharmacological analysis of long term parasympatholytic treatment. In: Magyar I (ed) Acta tertii conventus medicinae internae Hungarici. Gastroenterologia. Magyar I (ed), Akadémiai Kiadó, Budapest, pp 709–715Google Scholar
  25. Mózsik Gy, Pfeiffer CJ, Czimmer J (Guest Editors) (2001) Cell injury and protection in the gastrointestinal tract:from basic sciences to clinical perspectives. J Physiol Paris 95:1–494Google Scholar
  26. Mózsik Gy, Jávor T, Dobi S, Petrássy K, Szabó A (1967) Development of “pharmacological denervation phenomenon” in patients treated with atropine. Eur J Pharmacol 1:391–395CrossRefPubMedGoogle Scholar
  27. Mózsik Gy, Morón F, Jávor T (1982) Cellular mechanisms of the development of gastric mucosa damage and of gastrocytoprotection induced by prostacyclin in rats: a pharmacological study. Prostagland Leukot Med 9:71–84CrossRefGoogle Scholar
  28. Mózsik Gy, Bertelli A, Deák G, Nagy L, Patty I, Simon L, Tárnok F, Jávor T (1985) Some aspects of the critical evaluation of peptic ulcer therapy in patients. Int I Clin Pharmacol Res 5:447–455Google Scholar
  29. Mózsik Gy, Jávor T, Kitajima M, Pfeiffer CJ, Rainsford KD, Simon L, Szabó S (eds) (1989) Advances in gastrointestinal cytoprotection: topics 1987. Akadémiai Kiadó, BudapestGoogle Scholar
  30. Mózsik Gy, Király Á, Garamszegi M, Jávor T, Nagy L, Sütő G, Tóth Gy, Vincze Á (1991) Failure of prostacyclin, β-carotene, atropine, and cimetidine to produce gastric cyto- and general mucosal protection in surgically vagotomized rats. Life Sci 49:1383–1389CrossRefPubMedGoogle Scholar
  31. Mózsik Gy, Pár A, Csomós G, Kitajima M, Kondo M, Pfeiffer CJ, Rainsford KD, Sikirić P, Szabó S (eds) (1993) Cell injury and protection in the gastrointestinal tract:from basic sciences to clinical perspectives. Akadémiai Kiadó, BudapestGoogle Scholar
  32. Mózsik Gy, Abdel-Salam OME, Szolcsányi J (1997a) Capsaicin-Sensitive Afferent Nerves in Gastric Mucosal Damage and Protection. Akadémiaii Kiadó, BudapestGoogle Scholar
  33. Mózsik Gy, Nagy L, Pár A, Rainsford KD (eds) (1997b) Cell injury and protection in the gastrointestinal tract. Kluwer, DordrechtGoogle Scholar
  34. Mózsik Gy, Rácz I, Szolcsányi J (2005a) Gastroprotection by capsaicin in human healthy subjects. World J Gastroenterol 11:5180–5184PubMedGoogle Scholar
  35. Mózsik Gy, Rumi Gy, Dömötör A, Matuis Z, Figler M, Gasztonyi B, Papp E, Pár A, Pár G, Melegh B (2005b) Involvement of serum retinoids and activated proteic C in patients with oesophageal, gastric, liver, pancreatic and colorectal cancers in Hungary. World J Gastroenterol 11:7646–7650PubMedGoogle Scholar
  36. Mózsik Gy, Dömötör A, Abdel-Salam OME (2006) Molecular parmacological approach to drug actions on the afferent and efferent fibres of the vagal nerve in the gastric mucosal protection in rats. Inflammopharmacol 14:1–7CrossRefGoogle Scholar
  37. Mózsik Gy, Dömötör A, Rumi Gy, Szekeres Gy (2007a) Gastrointestinal cytoprotection: from basic science to clinical perspectives. Inflammopharmacology 15, 49-60.IGoogle Scholar
  38. Mózsik Gy, Szolcsányi J, Dömötör A (2007b) Capsaicin research as a new tool to approach of the human gastrointestinal physiology, pathology and pharmacology. Inflammopharmacology 15:232–245CrossRefPubMedGoogle Scholar
  39. Mózsik Gy, Past T, Dömötör A, Kuzma M, Perjési P (2010) Production of orally applicable new drug or drug combinations from natural origin capsaicinoids for human medical therapy. Curr Pharm Des 16:1197–1208Google Scholar
  40. Nagy L, Mózsik Gy, Feledi É, Ruzsa Cs, Vezekényi Zs, Jávor T (1984) Gastric microbleeding measurements during one day treatment indomethacin plus sodium-salycilate (1:10) in patients. Acta Physiol Hung 64:373–377PubMedGoogle Scholar
  41. Patty I, Benedek Sz, Deák G, Jávor T, Kenéz P, Nagy L, Simon L, Tárnok F, Mózsik Gy (1982) Controlled trial of vitamin A therapy in gastric ulcer. Lancet II:876CrossRefGoogle Scholar
  42. Patty I, Benedek Sz, Deák G, Jávor T, Kenéz P, Morón F, Nagy L, Simon L, Tárnok F (1983) Cytoprotective effect of vitamin A and its clinical importance in the treatment of patients with chronic gastric ulcer. Int J Tissue React 5:301–307PubMedGoogle Scholar
  43. Rainsford KD (1980) Reactions of the gastric mucosa to orally administered copper and other metal complexes. Agents Actions suppl. 8:369–387Google Scholar
  44. Rainsford KD (1989) The biochemical protective mechanisms against non-steroidal anti-inflammatory drug Induced GI mucosal damage. Acta Physiol Hung 72:261–278Google Scholar
  45. Rainsford KD (1992) Protective effects of the slow-release zinc complex, zinc monoglycerolate. [Glyzinc®], on the gastro-intestinal mucosae of rodents. Exptl Clinical Gastroenterol 1:349–360Google Scholar
  46. Rainsford KD, Whitehouse MW (1980a) Gastro-protective and anti-inflammatory properties of green-lipped mussel preparation (Perna canaliculus). Arzneim Forsch 30:2128–2132Google Scholar
  47. Rainsford KD, Whitehouse MW (1980b) Biochemical gastro-protection from acute ulceration induced by aspirin and related drugs. Biochem Pharmacol 29:1281–1289CrossRefPubMedGoogle Scholar
  48. Rainsford KD, Dieppe PA, Pritchard MH, Rhodes J, Leach H, Russell RI, Walker FS, Uphadyay R, Hort JF (1991) Protection from gastrointestinal side-effects by Azapropazone by its incorporation into a glucose-sodium acid citrate formulation. Aliment Pharmacol Ther 5:419–433CrossRefPubMedGoogle Scholar
  49. Robert A (1989) Adequate enzyme replacement after total pancreatectomy. JAMA 261:2638–2639CrossRefPubMedGoogle Scholar
  50. Robert A, Nezamis JE, Lancaster C, Hanchar A (1979) Cytoprotection by prostaglandins in rats: prevention of gastric necrosis produced by alcohol, HCl, NaOH, hypertonic NaCl, and thermal injury. Gastroenterology 77:433–443PubMedGoogle Scholar
  51. Shujaa N, Zadori ZS, Ronai AZ, Barna I, Mergl Z, Mozes MM, Gyires K (2009) Analysis of the effect of neuropeptides and cannabinoids in gastric mucosal defense initiated centrally in the rat. J Physiol Pharmacol 60(Suppl 7):93–100Google Scholar
  52. Sikirić P, Seiwerth S, Brcic L, Sever M, Klicek R, Radic B, Drmic D, Ilic S, Kolenc D (2010) Revised Robert’s cytoprotection and adaptive cytoprotection and stable gastric pentadecapeptide BPC 157: possible significance and implications for novel mediator. Curr Pharm Des 16:1214–1223CrossRefGoogle Scholar
  53. Szabo S (2009) “Gastric cytoprotection” – gastroprotection: 1979–2009 and beyond. J Physiol Pharmacol 60(Suppl 2):96Google Scholar
  54. Szabo S, Trier SJ, Frankel PW (1981) Sulfhydryl compounds may mediate gastric cytoprotection. Science 214:200–202CrossRefPubMedGoogle Scholar
  55. Szabó I, Bódis B, Nagy L, Mózsik Gy (1997) Comparative studies on isolated mucosal mixed cells and hepatoma, myeloma cell lines with ethanol, indomethacin and their combinations. Inflammopharmacology 5:21–28CrossRefGoogle Scholar
  56. Szolcsányi J (1984) Capsaicin and neurogenic inflammation:history and early findings. In: Chahl LA, Szolcsányi J, Lembeck F (eds) Antidromic vasodilatation and neurogenic inflammation. Chahl LA, Szolcsányi J, LembeckF (eds), pp 27–56. Akadémiai Kiadó, BudapestGoogle Scholar
  57. Taché Y (2009) Brain regulation of gastroprotection. J Physiol Pharmacol 60(Suppl 2):97Google Scholar
  58. Takeuchi K (2009) Prostaglandin EP receptors and their roles in gastrointestinal protection. J Physiol Pharmacol 60(Suppl 2):100Google Scholar
  59. Tarnawski A, Hollander D, Stachura J, Krause WJ, Gergely H (1985) Prostaglandin protection of the gastric mucosa against alcohol injury: a dynamic time related process. Gastroenterology 88:334–359PubMedGoogle Scholar
  60. Tarnawski A, Brzozowski T, Sarfeh IJ, Krause WJ, Ulich TR, Gergely H, Hollander D (1988) Prostaglandin protection of human isolated gastric glands against indomethacin and alcohol injury: evidence for direct cellular action of prostaglandin. J Clin Invest 88:1081–1089CrossRefGoogle Scholar
  61. Tarnawski A, Pai R, Deng X, Ahluwalia A, Khomenko T, Tanigawa T, Akahoshi T, Sandor Zs, Szabo S (2007) Aging gastropathy—novel mechanisms: hypoxia, upregulation of multifunctional phosphatase PTEN and proapoptotic factors. Gastroenterology 133:1938–1947CrossRefPubMedGoogle Scholar
  62. Tarnawski AS, Ahluwalia H, Gergely H (2009) Cytoprotection by hydrotalcite of aging gastric mucosa against NSAI- and ethanol-induced injury: cellular targets, molecular mechanisms and implications for new treatment of aging gastropathy. J Physiol Pharmacol 60(Suppl 2):104Google Scholar
  63. Tárnok F, Jávor T, Mózsik Gy, Nagy L, Patty I, Rumi Gy, Solt I (1979) A prospective multiclinical study comparing the effects of placebo, carbenoxolone, atropine, cimetidine in patients with duodenal ulcer. Drugs Exp Clin Res 5:157–166Google Scholar
  64. Whitehouse MW, Rainsford KD (1983) Prevention of gastrotoxicity of Aspirin and related drugs in rats by lithium salts and sodium thiocyanate. Toxicol Appl Pharmacol 68:323–327CrossRefPubMedGoogle Scholar
  65. Whitehouse MW, Rainsford KD, Taylor RM, Vernon-Roberts B (1990) Zinc Monoglycerolate: a slow-release source of zinc with anti-arthritic activity in rats. Agents Actions 31:47–58CrossRefPubMedGoogle Scholar

Copyright information

© Springer Basel AG 2010

Authors and Affiliations

  1. 1.Medical and Health Centre, First Department of MedicineUniversity of PécsPécsHungary

Personalised recommendations